Biological detection and diagnostics company PositiveID recently announced three new contracts for its two signature technologies.
PositiveID announced the agreements with NASA, UTC Aerospace Systems and the U.S. Department of Defense in conjunction with the defense contracting company Leidos.
PositiveID produced the handheld Firefly Dx and the Microfluidic Bioagent Autonomous Networked Detector (M-BAND). Both technologies are designed to quickly detect biological or chemical agents associated with weapons of mass destruction.
"In the near future, chemical weapon attacks, as we recently saw in Syria, could be detected early and mitigated, saving countless lives," William J. Caragol, the chairman and CEO of PositiveID, said.
Fully operational M-BAND units are expected to be on the market by 2015-2016, while Firefly is expected to enter prototype testing by 2015.
PositiveID also recently announced more $32.5 million in agreements with Boeing and the U.S. Department of Homeland Security Science and Technology Directorate. Boeing could deploy more than 875 M-BAND units by 2020, and Caragol said the Firefly is positioned to capitalize on the U.S. government's BioWatch program to develop defenses against biological attacks. BioWatch could represent a $3 billion opportunity for PositiveID and other companies developing biological and chemical defense technologies.